1. Home
  2. CTSH vs UTHR Comparison

CTSH vs UTHR Comparison

Compare CTSH & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cognizant Technology Solutions Corporation

CTSH

Cognizant Technology Solutions Corporation

HOLD

Current Price

$58.10

Market Cap

26.7B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$541.60

Market Cap

23.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTSH
UTHR
Founded
1994
1996
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.7B
23.1B
IPO Year
1998
1999

Fundamental Metrics

Financial Performance
Metric
CTSH
UTHR
Price
$58.10
$541.60
Analyst Decision
Buy
Buy
Analyst Count
29
15
Target Price
$65.10
★ $644.36
AVG Volume (30 Days)
★ 5.2M
569.5K
Earning Date
10-29-2026
10-28-2026
Dividend Yield
★ 2.27%
N/A
EPS Growth
1.11
★ 13.07
EPS
1.39
★ 13.07
Revenue
★ $21,108,000,000.00
$1,483,300,000.00
Revenue This Year
$5.15
N/A
Revenue Next Year
$4.74
$10.21
P/E Ratio
$41.69
★ $41.12
Revenue Growth
★ 6.95
2.38
52 Week Low
$37.08
$409.15
52 Week High
$87.03
$609.35

Technical Indicators

Market Signals
Indicator
CTSH
UTHR
Relative Strength Index (RSI) 47.33 59.81
Support Level $45.48 $526.30
Resistance Level $63.61 $567.35
Average True Range (ATR) 1.91 17.13
MACD -0.34 7.90
Stochastic Oscillator 28.49 61.69

Price Performance

Historical Comparison
CTSH
UTHR

About CTSH Cognizant Technology Solutions Corporation

Cognizant Technology Solutions is a multinational IT services provider that offers a range of consulting and business process outsourcing services. Originally founded in India, the company is headquartered in the US and serves enterprise customers spanning the financial services, healthcare, and resources industries. With most of its workforce located in India, Cognizant leverages a global delivery model that helps clients outsource their IT needs to offshore labor.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: